Policy | May 24, 2021
NATCO Pharma receives USFDA approval for Lenalidomide capsules
NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.
NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.
Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday
The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
The trial met its pre-specified primary endpoint, demonstrating that PDP-716 dosed once daily is equivalent to Alphagan P 0.1% dosed 3 times a day
Proactively engaging with foreign vaccine manufacturers like Moderna, Pfizer etc., to apply for Emergency Use Authorization in India so that these vaccines can be easily imported and made available in India
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
First company in the world to launch Ryaltris-AZ, as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
Subscribe To Our Newsletter & Stay Updated
